Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
A new study has highlighted the benefit of routine antibody testing in suspected cases of celiac disease. While these data prove the merit of serological testing, awareness of the disease remains a significant issue. Indeed, with almost no treatment options available, the development of an effective pharmacological therapy offers the potential to reap significant returns from this untapped market.
Published By Datamonitor
|
21 Dec 2009 |
|
Expert View
|
Clinical decision support tools, technologies that provide information to aid the diagnosis and treatment of patients, are set to make dramatic changes to the practice of medicine, according to a new report by Datamonitor. However, the report also predicts that aspects of medical culture will prove barriers to adoption.
Published By Datamonitor
|
24 Jul 2008 |
|
Expert View
|
In a pharmaceutical market where the days of the primary care blockbuster-selling drug appear numbered, the days of pharma sales representatives having time to visit physicians with drug samples are also waning. Reps must now embrace internet technology to ensure samples are efficiently distributed to physicians and also take on the role of educators in their dynamic relationships with physicians.
Published By Datamonitor
|
15 Mar 2006 |
|
Expert View
|
Datamonitor believes that, through its brand strength, Google's entry into the personal health record market is likely to make personal health records a success and result in consumers becoming more knowledgeable about their health. While other companies have developed personal health records, the significance of Google's entry cannot be underestimated due to its unparalleled consumer reach.
Published By Datamonitor
|
06 Mar 2008 |
|
Expert View
|
Staphylococcus aureus bacteria have become a key concern in both the hospital and community setting. The spread of resistant strains, such as MRSA, underlines the urgent need for new strategies to treat and prevent these infections. Prophylactic vaccination of target groups could be a useful tool, but prudent group selection combined with alternative prevention strategies, will be key to success.
Published By Datamonitor
|
17 Jul 2008 |
|
Expert View
|
Early successes in healthcare interoperability are paving the way for more health information exchanges in the near to mid future. Separate networks, including personal health records, will connect to form larger networks, and despite continuing skepticism surrounding the burgeoning technology, health information exchanges look set to become a typical part of the patient experience.
Published By Datamonitor
|
13 Nov 2008 |
|
Expert View
|
Growing regulatory pressure and competition from generics will drive adoption of product lifecycle management software and services in the pharmaceutical industry. Datamonitor estimates spending on product lifecycle management software by the pharmaceutical industry in Europe, North America, China and Japan to total $460.2 million by the end of 2007 and expects this to more than double by 2012.
Published By Datamonitor
|
21 Sep 2007 |
|
Expert View
|
Although many newer pharmacovigilance solutions are still in the nascent stages, and despite pharmaceutical companies' reluctance to adopt them, it is becoming increasingly obvious that these tools will play an essential role in protecting public health. As drug safety regulations increase, signal detection technologies will aid in the costly act of identifying and managing adverse drug events.
Published By Datamonitor
|
06 Jun 2008 |
|
Expert View
|
Aging populations, a growing prevalence of chronic diseases, and greater use of expensive treatments are among the factors putting pressure on healthcare budgets in developed and developing markets. Consequently, countries are resorting to a range of strategies including pricing and reimbursement cuts and bolstering generic uptake, in turn exerting negative pressures on pharmaceutical companies.
Published By Datamonitor
|
19 Apr 2011 |
|
Expert View
|
Roche has initiated efforts to acquire all outstanding shares in Genentech for approximately $43.7 billion, having purchased 55.9% of the company in 1990. While Genentech has historically operated independently from its parent company, it remains to be seen whether the merger will damage an operating structure which has allowed the biotech firm to drive Roche's growth performance in recent years.
Published By Datamonitor
|
23 Jul 2008 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.